Sai Parenterals Q1 FY27 Revenue ₹182 Cr, PAT ₹8 Cr
Sai Parenterals Ltd announced its un-audited financial results for the quarter ended June 30, 2026. Consolidated revenue from operations stood at ₹178.7 crore, with total revenue at ₹182.4 crore. Gross profit was ₹76.2 crore (41.8% margin), EBITDA ₹27.3 crore (14.9% margin), and Profit After Tax (PAT) ₹7.9 crore (4.3% margin). The results reflect the full quarter consolidation of Noumed Pharmaceuticals. Standalone revenue was ₹56.2 crore, with PAT at ₹8.9 crore. The company also proposed a variation in IPO proceeds utilization to acquire majority stakes in two pharmaceutical assets, including a 60% stake in Saicriti Pharma Private Limited for ₹83.83 crore to build a critical-care injectable facility.
Key Highlights
- Consolidated revenue grew to ₹182.4 crore in Q1 FY27.
- PAT stood at ₹7.9 crore, with a margin of 4.3%.
- Standalone revenue saw a 174.8% YoY growth to ₹56.2 crore.
- Proposed acquisition of 60% stake in Saicriti Pharma for ₹83.83 crore.
- Variation in IPO proceeds to fund majority stake acquisitions.
Price Impact
More from SAIPARENT